Dec. 15 - Lilly boosts sales forecasts, insurers sue HIV drugmakers and broadening CAR-T use

Humana, Centene sue drugmakers, alleging anticompetitive practices on HIV drugs; CAR-T therapy trials show promise for earlier use in lymphoma; Intercept, awaiting needed trial data, pulls its NASH drug application in Europe View online | Signup | Forward

Commercialization weekly Dec.​ 15,​ 2021 | This week's commercialization news and insights for biopharma leaders   BROUGHT TO YOU BY — Medidata Acorn AI Are You Ready for Your Commercial Drug Launch? Download the eBook for 6 Critical Factors for a Successful Commercial Launch Strategy. Download Now.   Lilly ups revenue forecast amid windfall from COVID-19 drugs While the boost from its COVID-19 treatments might be temporary, Lilly believes next year's revenue will hold up thanks to newer products. Also on the horizon are potential approvals for key Alzheimer's and diabetes medicines. Humana, Centene sue drugmakers, alleging anticompetitive practices on HIV drugs The insurers filed suit against Gilead, J&J, Bristol Myers Squibb and Teva, claiming the drugmakers conspired to protect lucrative HIV drugs from competition. UPDATED CAR-T therapy trials show promise for earlier use in lymphoma Study results presented at ASH suggest Gilead's Yescarta and Bristol Myers Squibb's Breyanzi could become replacements for stem cell transplants in treating the blood cancer. Sponsored Content by BioPharma Dive's studioID How to accelerate commercial success Advances in mRNA technology have increased pressure on biotech leaders to deliver insights fast. Discover how to use high-dimensional biology to enable faster discoveries and commercial success in this playbook. Intercept, awaiting needed trial data, pulls its NASH drug application in Europe The biotech has lost much of its market value amid delays and regulatory questions for obeticholic acid. But the failures of other drugmakers still leave the company with a chance to rebound. Read more news From Our Library Webinar - on demand Getting Your Data Aggregation Contract Right in Pharma IQVIA Playbook Accelerating Biotech Discovery With High-Dimensional Biology and Bioinformatics BD Biosciences Playbook Critical & Time-Sensitive Cold Chain Shipments Best Practices Tive View all resources What We're Reading FiercePharma AbbVie's Rinvoq, Pfizer's Xeljanz win new uses after extended reviews as JAK safety woes linger Endpoints News Clinical trials at local pharmacies? A natural fit and more likely than ever: analyst Adweek CDC Social Campaign Aimed at Vaccine-Hesitant Multicultural Gen-Z, Millennials Healthcare Dive New CVS primary care locations to include physicians for first time Suggest a story we should read Upcoming Event Partnering for Success: Doing Study Start-Up Right in the Context of Decentralized Studies Jan. 27, 2022 - Jan. 27, 2022 | Webinar 2pm ET Dive Into a Topic Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy Share BioPharma Dive: Commercialization Weekly with others and get rewarded. You've referred 0 readers. To become an official Dive Insider, just successfully refer 10 contacts to BioPharma Dive: Commercialization Weekly. Here's your link to share: https://www.biopharmadive.com/signup/insiders/?signup_referred_by=5f93078d7aa51972095c9316

More Than A Newsletter Related Publications Healthcare Dive | MedTech Dive Connect With Us Twitter | Facebook | LinkedIn Editorial Contact an editor | Meet the team Advertising Contact our team About BioPharma Dive BioPharma Dive provides in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships. BioPharma Dive is a leading industry publication operated by Industry Dive. Our business journalists spark ideas and shape agendas for 10+ million decision makers in the most competitive industries. Sign up for the newsletter This email is optimized for display on mobile phones. BioPharma Dive: Commercialization Weekly is a product of Industry Dive, Inc. 1255​ 23rd Street NW, Suite 550, Washington,​ DC 20037. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to edwardlorilla1986.acciyo123@blogger.com. You can unsubscribe anytime. See our full privacy policy.

Sign up | Manage subscription | Advertise with us | Submit story tip